182 related articles for article (PubMed ID: 22322844)
21. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells.
Huang S; Sinicrope FA
Cancer Res; 2008 Apr; 68(8):2944-51. PubMed ID: 18413764
[TBL] [Abstract][Full Text] [Related]
22. Programmed cell death 4 (PDCD4) enhances the sensitivity of gastric cancer cells to TRAIL-induced apoptosis by inhibiting the PI3K/Akt signaling pathway.
Wang WQ; Zhang H; Wang HB; Sun YG; Peng ZH; Zhou G; Yang SM; Wang RQ; Fang DC
Mol Diagn Ther; 2010 Jun; 14(3):155-61. PubMed ID: 20560677
[TBL] [Abstract][Full Text] [Related]
23. TRAIL-induced apoptosis in human vascular endothelium is regulated by phosphatidylinositol 3-kinase/Akt through the short form of cellular FLIP and Bcl-2.
Alladina SJ; Song JH; Davidge ST; Hao C; Easton AS
J Vasc Res; 2005; 42(4):337-47. PubMed ID: 15985761
[TBL] [Abstract][Full Text] [Related]
24. Response of bladder carcinoma cells to TRAIL and antisense oligonucleotide, Bcl-2 or clusterin treatments.
Sun B; Moibi JA; Mak A; Xiao Z; Roa W; Moore RB
J Urol; 2009 Mar; 181(3):1361-71. PubMed ID: 19157446
[TBL] [Abstract][Full Text] [Related]
25. Synergy between phosphatidylinositol 3-kinase/Akt pathway and Bcl-xL in the control of apoptosis in adenocarcinoma cells of the lung.
Qian J; Zou Y; Rahman JS; Lu B; Massion PP
Mol Cancer Ther; 2009 Jan; 8(1):101-9. PubMed ID: 19139118
[TBL] [Abstract][Full Text] [Related]
26. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
Liu Y; Chen X; Luo Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
[TBL] [Abstract][Full Text] [Related]
27. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells.
Taniai M; Grambihler A; Higuchi H; Werneburg N; Bronk SF; Farrugia DJ; Kaufmann SH; Gores GJ
Cancer Res; 2004 May; 64(10):3517-24. PubMed ID: 15150106
[TBL] [Abstract][Full Text] [Related]
28. EGCG sensitizes human nasopharyngeal carcinoma cells to TRAIL-mediated apoptosis by activation NF-κB.
Li P; Li S; Yin D; Li J; Wang L; Huang C; Yang X
Neoplasma; 2017; 64(1):74-80. PubMed ID: 27881007
[TBL] [Abstract][Full Text] [Related]
29. Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells.
Nencioni A; Wille L; Dal Bello G; Boy D; Cirmena G; Wesselborg S; Belka C; Brossart P; Patrone F; Ballestrero A
Clin Cancer Res; 2005 Jun; 11(11):4259-65. PubMed ID: 15930365
[TBL] [Abstract][Full Text] [Related]
30. Cell detachment modulates TRAIL resistance in ovarian cancer cells by downregulating the phosphatidylinositol 3-kinase/Akt pathway.
Lane D; Cartier A; Rancourt C; Piché A
Int J Gynecol Cancer; 2008; 18(4):670-6. PubMed ID: 17868340
[TBL] [Abstract][Full Text] [Related]
31. ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein.
Wang G; Zhan Y; Wang H; Li W
Cancer Chemother Pharmacol; 2012 Mar; 69(3):799-805. PubMed ID: 22037880
[TBL] [Abstract][Full Text] [Related]
32. ABT-199-mediated inhibition of Bcl-2 as a potential therapeutic strategy for nasopharyngeal carcinoma.
Wang Y; Wang Y; Fan X; Song J; Wu H; Han J; Lu L; Weng X; Nie G
Biochem Biophys Res Commun; 2018 Sep; 503(3):1214-1220. PubMed ID: 30017199
[TBL] [Abstract][Full Text] [Related]
33. PI3K inhibitor LY294002 inhibits activation of the Akt/mTOR pathway induced by an oncolytic adenovirus expressing TRAIL and sensitizes multiple myeloma cells to the oncolytic virus.
Tong Y; Zhu W; Huang X; You L; Han X; Yang C; Qian W
Oncol Rep; 2014 Apr; 31(4):1581-8. PubMed ID: 24535016
[TBL] [Abstract][Full Text] [Related]
34. Blocking PI3K/Akt signaling attenuates metastasis of nasopharyngeal carcinoma cells through induction of mesenchymal-epithelial reverting transition.
Jiang H; Gao M; Shen Z; Luo B; Li R; Jiang X; Ding R; Ha Y; Wang Z; Jie W
Oncol Rep; 2014 Aug; 32(2):559-66. PubMed ID: 24889918
[TBL] [Abstract][Full Text] [Related]
35. Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways.
Gunda V; Bucur O; Varnau J; Vanden Borre P; Bernasconi MJ; Khosravi-Far R; Parangi S
Cell Death Dis; 2014 Mar; 5(3):e1104. PubMed ID: 24603332
[TBL] [Abstract][Full Text] [Related]
36. NVP-BKM120 potentiates apoptosis in tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cell lines via upregulation of Noxa and death receptor 5.
Foster KA; Jane EP; Premkumar DR; Morales A; Pollack IF
Int J Oncol; 2015 Aug; 47(2):506-16. PubMed ID: 26044191
[TBL] [Abstract][Full Text] [Related]
37. Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells.
Metwalli AR; Khanbolooki S; Jinesh G; Sundi D; Shah JB; Shrader M; Choi W; Lashinger LM; Chunduru S; McConkey DJ; McKinlay M; Kamat AM
Cancer Biol Ther; 2010 Nov; 10(9):885-92. PubMed ID: 20814238
[TBL] [Abstract][Full Text] [Related]
38. Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells.
Lane D; Robert V; Grondin R; Rancourt C; Piché A
Int J Cancer; 2007 Sep; 121(6):1227-37. PubMed ID: 17534891
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine.
Xie X; Tang B; Zhou J; Gao Q; Zhang P
Oncol Rep; 2013 Aug; 30(2):773-82. PubMed ID: 23743572
[TBL] [Abstract][Full Text] [Related]
40. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy.
Wang S; El-Deiry WS
Proc Natl Acad Sci U S A; 2003 Dec; 100(25):15095-100. PubMed ID: 14645705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]